discontinued

AP00352PU-N Influenza A H5N1 (Neuraminidase) antibody

See related secondary antibodies

Search for all "Influenza A H5N1"

Quick Overview

Rabbit anti Influenza A H5N1

AP00352PU-N

Product Description for Influenza A H5N1

Rabbit anti Influenza A H5N1.
Properties: (Neuraminidase)
Presentation: Aff - Purified
Product is tested for Enzyme Immunoassay.

Properties for Influenza A H5N1

Product Category Primary Antibodies
Quantity 0.1 mg
Synonyms Avian Influenza A H5N1 H5 Hemagglutinin
Presentation Aff - Purified
Applications E
Clonality Polyclonal
Host Rabbit
Shipping to Worldwide
PDF datasheet View Datasheet
Manufacturer OriGene Technologies GmbH
Material safety datasheet MSDS for Polyclonal Antibodies (de)

Datasheet Extract

Immunogen
Immunogen:
Synthetic peptide corresponding to 15 amino acids at the C-terminal of the Neuraminidase protein.
Remarks:
Genbank accession no. CAC95053
Property Neuraminidase
Application ELISA.
Background Catalyzes the removal of terminal sialic acid residues from viral and cellular glycoconjugates. Cleaves off the terminal sialic acids on the glycosylated HA during virus budding to facilitate virus release. Additionally helps virus spread through the circulation by further removing sialic acids from the cell surface. These cleavages prevent self-aggregation and ensure the efficient spread of the progeny virus from cell to cell. Otherwise, infection would be limited to one round of replication. Described as a receptor-destroying enzyme because it cleaves a terminal sialic acid from the cellular receptors. May facilitate viral invasion of the upper airways by cleaving the sialic acid moities on the mucin of the airway epithelial cells. Likely to plays a role in the budding process through its association with lipid rafts during intracellular transport. May additionally display a raft-association independent effect on budding. Plays a role in the determination of host range restriction on replication and virulence. Sialidase activity in late endosome/lysosome traffic seems to enhance virus replication.
Concentration 1.0 mg/ml
General Readings
  1. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003 Jan 8;289(2):179-86. PubMed PMID: 12517228.
  2. Alexander, D.J., (2000), "A review of avian influenza. Proceedings of the European Society for Veterinary Virology (ESVV) Symposium on Influenza Viruses of Wild and Domestic Animals", Vet. Microbiol., 74, 3-13.
  3. Shortridge KF, Zhou NN, Guan Y, Gao P, Ito T, Kawaoka Y, et al. Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Virology. 1998 Dec 20;252(2):331-42. PubMed PMID: 9878612.
  4. Buxton Bridges C, Katz JM, Seto WH, Chan PK, Tsang D, Ho W, et al. Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong. J Infect Dis. 2000 Jan;181(1):344-8. PubMed PMID: 10608786.
  5. Hulse DJ, Webster RG, Russell RJ, Perez DR. Molecular determinants within the surface proteins involved in the pathogenicity of H5N1 influenza viruses in chickens. J Virol. 2004 Sep;78(18):9954-64. PubMed PMID: 15331729. (Free PMC Article available, 7 images available)
Storage Store the antibody undiluted at 2-8°C.
Shelf life: one year from despatch.
Format
Purification:
Immunoaffinity Chromatography.
Buffer System:
PBS containing 0.02% Sodium Azide as preservative.
State:
Liquid purified Ig fraction.
Aff - Purified
Specificity
Specificity:
Neuraminidase protein from the H5N1 strain of avian influenza (C-terminal).

Accessory Products

  • LinkedIn